 Tenofovir DF is hydrolyzed enzymatically to tenofovir which exhibits anti-HIV activity.It was developed by the synthesis and broad spectrum antiviral activity of 2,3-dihydroxypropyladenine.Tenofovir DF was the first nucleotide reverse-transcriptase inhibitor approved by the FDA for the treatment of HIV-1 infection in October 2001.